US 11,919,865 B2
Processes for preparing AG-10, its intermediates, and salts thereof
Pooran Chand, San Francisco, CA (US); Yogesh Kumar Gupta, San Francisco, CA (US); Rakesh Kumar Kumawat, San Francisco, CA (US); Mamoun Alhamadsheh, San Francisco, CA (US); and Robert Zamboni, San Francisco, CA (US)
Assigned to EIDOS THERAPEUTICS, INC., San Francisco, CA (US)
Filed by EIDOS THERAPEUTICS, INC., San Francisco, CA (US)
Filed on Jun. 17, 2021, as Appl. No. 17/350,066.
Application 16/676,931 is a division of application No. 15/932,327, filed on Feb. 16, 2018, granted, now 10,513,497, issued on Dec. 24, 2019.
Application 17/350,066 is a continuation of application No. 16/676,931, filed on Nov. 7, 2019, granted, now 11,078,162.
Claims priority of provisional application 62/460,576, filed on Feb. 17, 2017.
Prior Publication US 2022/0041558 A1, Feb. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 231/12 (2006.01); C07C 309/04 (2006.01); C07C 309/30 (2006.01)
CPC C07D 231/12 (2013.01) [C07C 309/04 (2013.01); C07C 309/30 (2013.01); C07B 2200/13 (2013.01)] 16 Claims
 
1. A method of treating a transthyretin (TTR) amyloid disease comprising administering to a subject in need thereof Crystalline Form Type A of Formula IX as its HCl salt

OG Complex Work Unit Chemistry
characterized by an X-ray powder diffraction pattern comprising peaks at 12.0, 21.8, 25.9, 26.7, and 27.9 degrees 2θ (±0.2 degrees 2θ).